Atopic Dermatitis (Adult Recalcitrant, EASI >21)

Patient Summary

Is this FDA-cleared for this use?

Not FDA-cleared for atopic dermatitis. The FDA cleared medicinal leeches in 2004 (K040187) only for venous congestion in microsurgical reconstruction. Use for atopic dermatitis is investigational.

What evidence exists?

Tier C (investigational). A single small case series (n=12) suggests possible improvement; there are no randomized controlled trials. Evidence-based therapy for recalcitrant adult atopic dermatitis is dupilumab, tralokinumab, or oral JAK inhibitors (upadacitinib, abrocitinib), with high-potency topical corticosteroids and calcineurin inhibitors for flares. AAD guidelines recommend stepwise escalation through biologics before considering experimental adjuncts.

Main risks

• Bleeding from bite sites for 6 to 24 hours after each leech detaches
• Itching, redness, and irritation at bite sites lasting days to weeks
• Koebner-like flare of eczema at bite locations in actively inflamed skin
• Local skin infection or, rarely, Aeromonas infection from leech gut bacteria
• Eczema herpeticum or impetiginization if applied to broken or weeping skin
• Allergic reaction to leech saliva (uncommon but possible)
• Post-inflammatory hyperpigmentation, especially in darker skin
• Delay of evidence-based dupilumab or JAK-inhibitor therapy

Who should not consider this

• Patients with active eczema herpeticum or impetiginized eczema
• Patients on JAK inhibitors with severe immunosuppression
• Patients with widespread excoriation or secondary bacterial infection
• Patients on anticoagulants, with hemophilia, or with severe anemia (Hb <10)
• Pregnant or breastfeeding patients
• Patients who have not been offered or trialed dupilumab or JAK inhibitors

What to ask your clinician

• Have I been offered dupilumab, tralokinumab, or an oral JAK inhibitor by a dermatologist?
• What evidence supports leech therapy specifically for atopic dermatitis like mine?
• Will leech application risk triggering a flare or eczema herpeticum at bite sites?
• What is the practitioner's Aeromonas-prevention plan and antibiotic protocol?
• Are leeches from an FDA-registered supplier and used only once?
• How will we know if treatment is working — by EASI score, photographs, or symptoms?
• What is the cost and is it covered by insurance? (typically not covered)

When to seek urgent care

• Rapidly spreading vesicular or punched-out lesions (suspect eczema herpeticum — emergency)
• Spreading redness, warmth, pus, or red streaks around bite sites (cellulitis)
• Fever above 38.0 C / 100.4 F or chills
• Bleeding from a bite site lasting more than 24 hours
• Hives, facial or tongue swelling, throat tightness, or breathing difficulty
• Severe flare with extensive skin denudation or signs of systemic illness